{"schema_version":"secwatch.filing_event.v1","accession":"0001944048-26-000141","form_type":"8-K","ticker":"KVUE","cik":"0001944048","company_name":"Kenvue Inc.","filed_at":"2026-08-06T10:48:04+00:00","discovered_at":"2026-08-06T10:50:03.319191+00:00","generated_at":"2026-08-06T10:50:08.152555+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kenvue Q2 net sales +3.0%, adj. EPS $0.31 (+7% YoY); reaffirms Q4 Kimberly-Clark deal close","bullets":["Net sales $3.0B, +3.0% YoY; organic sales +1.6% driven by value realization +0.9% and volume +0.7%.","Diluted EPS $0.24 (+9% YoY); adjusted diluted EPS $0.31 (+7% YoY); adjusted gross margin 60.2%.","Skin Health & Beauty led with +5.1% net sales; Self Care +2.2%, Essential Health +2.3%.","FDA approved Tylenol with Naproxen (first OTC fixed-dose combo); 3-year exclusivity, launching soon.","Pending Kimberly-Clark acquisition on track for Q4 2026; no forward guidance provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001944048-26-000141","json":"https://secwatch.observer/filing/0001944048-26-000141.json","markdown":"https://secwatch.observer/filing/0001944048-26-000141.md","text":"https://secwatch.observer/filing/0001944048-26-000141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1944048/000194404826000141/0001944048-26-000141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1944048/000194404826000141/kvue-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T10:50:08.152555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}